Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer (RADIT)

This study has been completed.
Sponsor:
Collaborator:
Novartis
Information provided by (Responsible Party):
Hannover Medical School
ClinicalTrials.gov Identifier:
NCT01242631
First received: November 16, 2010
Last updated: February 24, 2015
Last verified: February 2015
  Purpose

The purpose of this study is to determine whether the drug everolimus is effective in the treatment of patients with relapsed cancer of the testis. This is a phase II study where all patients will receive the study drug (everolimus 10 mg daily). The primary endpoint of the study is the rate of patients that have no progressive disease after 12 weeks of treatment. Twenty-five evaluable patients will be treated in this study.


Condition Intervention Phase
Testicular Cancer
Germ Cell Cancer
Drug: Everolimus
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Single Arm, Open-label Multicenter Phase II Trial of Everolimus in Patients With Relapsed/Refractory Germ Cell Cancer

Resource links provided by NLM:


Further study details as provided by Hannover Medical School:

Primary Outcome Measures:
  • Progression-free rate at 12 weeks [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Percentage of patients that have not progressed after 12 weeks of treatment.


Secondary Outcome Measures:
  • Objective response rate [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Safety profile [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

Enrollment: 25
Study Start Date: November 2010
Study Completion Date: March 2014
Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Everolimus 10 mg daily Drug: Everolimus
Everolimus 10 mg orally per day.
Other Name: Afinitor

Detailed Description:

Rationale

Patients with metastatic germ cell cancer and relapse after two or more courses of cisplatin-based chemotherapy or after high-dose chemotherapy have a poor prognosis and few treatment options. Everolimus is a derivative of rapamycin and acts as a signal transduction inhibitor. Its target is mTOR (mammalian target of rapamycin), a key protein kinase regulating cell growth, proliferation and survival. The mTOR pathway activity is modulated by the PI3K1AKT pathway and is known to be deregulated in numerous human cancers, including germ cell tumors. Everolimus is being investigated as an anticancer agent based on its potential to act:

  • Directly on tumor cells by inhibiting tumor cell growth and proliferation
  • Indirectly by inhibiting angiogenesis leading to reduced tumor vascularity

Study design

An open-label, single arm, non-randomized, single stage phase II study. Screening phase: Baseline evaluations will be performed within 2 weeks before the first dose of study drug. Treatment phase: All patients will receive everolimus until disease progression (by RECIST or tumor markers) or unacceptable toxicity or study discontinuation for other reasons. A treatment cycle consists of 3 weeks. Dose reductions and dose interruptions (for up to 2 weeks) are allowed for intolerable toxicity. Follow-up phase: All patients will be followed for survival.

Visit schedule

Tumor Response and progression will be assessed using the RECIST criteria and assessments with tumor markers. Tumor measurements by a CT scan or MRI will be performed at screening within 2 weeks prior to the first dose of study drug. During the study period, the CT scan/MRI will be performed every 6 weeks (± one week), and at the time of discontinuation of study drug (within 2 weeks). The same type of scan (CT or MRI) used at screening must be used for all subsequent follow-up assessments. A partial or a complete response warrants a confirmation no sooner than 4 weeks and no later than 6 weeks after its observation.

Tumor markers (AFP, HCG) will be assessed every 3 weeks. A tumor marker reduction > 90% without an increase in tumor size is considered a partial response. A tumor marker increase > 25% without an increase in tumor size is considered progressive disease when confirmed 3 weeks after its observation.

Translational research

The following retrospective pathological examinations of tumor samples will be performed in those patients that gave additional informed consent:

  • immunohistochemistry for the mismatch repair genes hMLH1, hMSH2, hMSH6, and PMS2, and the cell signalling effectors pMAPK, pAKT, pS6K and PTEN.
  • mutation analysis for PTEN, BRAF, p53, and examination of microsatellite instability This information will be correlated with treatment response (CR, PR, SO or PD) at week 12 in an exploratory analysis.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male patients >= 18 years old.
  • Patients with histologically proven seminomatous or non-seminomatous germ cell cancer
  • Disease progression during cisplatin-based chemotherapy or
  • Disease progression or relapse after high-dose chemotherapy or
  • Disease progression or relapse after at least 2 different cisplatin-based regimens and contraindications for high-dose chemotherapy.
  • Patients must have received prior combination chemotherapy with gemcitabine, oxaliplatin and paclitaxel (GOP). Prior treatment with a combination of two of these drugs is allowed in case of contraindications for GOP.
  • Disease progression at study entry: progressive disease according to RECIST criteria in baseline examinations or tumor marker increase > 25% within 4 weeks before study entry.
  • ECOG performance status <= 2.
  • Life expectancy >= 3 months.
  • Adequate bone marrow function: absolute neutrophil count >= 1.5 x 109/1, platelets >= 75 x 109/1, hemoglobin >= 9 g/dl.
  • Adequate liver function: serum bilirubin: <= 1.5x ULN, ALT and AST <= 2.5x ULN. For patients with known liver metastases: AST and ALT <= 5x ULN.
  • Adequate renal function: serum creatinine <= 2.0x ULN.
  • Patients must be surgically sterile or must agree to use effective contraception during study treatment.
  • Signed written informed consent.

Exclusion Criteria:

  • Systemic antitumor treatment within 21 days before study entry.
  • Simultaneous radiotherapy of the only target lesion(s).
  • Patients who have undergone major surgery within 4 weeks prior to starting study drug (e.g. intra-thoracic, intra-abdominal, or intra-pelvic) or significant traumatic injury, or who have not recovered from the side effects of any of the above
  • Patients who have previously received mTOR inhibitors (sirolimus, temsirolimus, everolimus).
  • Patients receiving chronic systemic treatment with corticosteroids (dose of >= 20 mg/day methylprednisone equivalent) or another immunosuppressive agent.
  • Patients with unstable angina pectoris, myocardial infarction <= 6 months prior to first study treatment, congestive heart failure NYHA III-IV or serious uncontrolled cardiac arrhythmias.
  • Patients with severely impaired lung function: spirometry or DLCO < 50% of the normal predicted value.
  • Uncontrolled diabetes: fasting serum glucose > 2.0x ULN.
  • Patients with an active or uncontrolled infection, incl. chronic Hepatitis B or C
  • Patients who have a history of another primary malignancy and are off treatment for <= 3 years, with the exception of non-melanoma skin cancer.
  • Patients who have participated in another clinical trial within 30 days before study entry.
  • Other serious medical conditions that could impair the ability of the patient to participate in the study.
  • Patients unwilling or unable to comply with the protocol.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01242631

Locations
Germany
Vivantes Klinikum am Urban
Berlin, Germany, 10967
Universitatsklinikum Essen
Essen, Germany, 45122
Universitatsklinikum Hamburg-Eppendorf
Hamburg, Germany, 20246
Hannover Medical School
Hannover, Germany, 30625
Universitatsklinikum Schieswig-Holstein - Campus Kiel
Kiel, Germany, 24105
Universitatsklinikum Marburg
Marburg, Germany, 35043
Klinikum Harlaching München
München, Germany, 81545
Universitatsklinikum der Eberhard-Karls-Universitat Tübingen
Tübingen, Germany, 72076
Sponsors and Collaborators
Hannover Medical School
Novartis
Investigators
Principal Investigator: Martin H Fenner, MD Hannover Medical School
  More Information

Additional Information:
No publications provided

Responsible Party: Hannover Medical School
ClinicalTrials.gov Identifier: NCT01242631     History of Changes
Other Study ID Numbers: CRAD001CDE21T, 2009-014383-18
Study First Received: November 16, 2010
Last Updated: February 24, 2015
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Neoplasms, Germ Cell and Embryonal
Testicular Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Male
Genital Neoplasms, Male
Gonadal Disorders
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Testicular Diseases
Urogenital Neoplasms
Everolimus
Sirolimus
Anti-Bacterial Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antifungal Agents
Antineoplastic Agents
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on April 16, 2015